Novo Nordisk
NVO
1,531 hedge funds and large institutions have $22.5B invested in Novo Nordisk in 2025 Q1 according to their latest regulatory filings, with 140 funds opening new positions, 627 increasing their positions, 562 reducing their positions, and 247 closing their positions.
12% more repeat investments, than reductions
Existing positions increased: 627 | Existing positions reduced: 562
0.4% less ownership
Funds ownership: 9.97% → 9.57% (-0.4%)
8% less funds holding
Funds holding: 1,665 → 1,531 (-134)
22% less funds holding in top 10
Funds holding in top 10: 32 → 25 (-7)
23% less capital invested
Capital invested by funds: $29.1B → $22.5B (-$6.6B)
26% less call options, than puts
Call options by funds: $987M | Put options by funds: $1.34B
43% less first-time investments, than exits
New positions opened: 140 | Existing positions closed: 247
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
+$317M |
| 2 |
Capital International Investors
Los Angeles,
California
|
+$228M |
| 3 |
ClearBridge Investments
New York
|
+$194M |
| 4 |
Amundi
Paris,
France
|
+$134M |
| 5 |
Two Sigma Investments
New York
|
+$108M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GQG Partners
Ft. Lauderdale,
Florida
|
-$1.06B |
| 2 |
Polen Capital Management
Boca Raton,
Florida
|
-$446M |
| 3 |
Capital World Investors
Los Angeles,
California
|
-$350M |
| 4 |
Renaissance Technologies
New York
|
-$123M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$94.4M |
NVO Hedge Fund Activity: Q1 2025 in Review
1,531 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in Novo Nordisk (NVO) for Q1 2025, worth a combined $22.5B — down 23% from $29.1B a quarter earlier.
Sellers outnumbered buyers: 247 funds closed out of NVO and 140 opened new positions — a net loss of 107 holders — while 562 trimmed existing stakes and 627 added.
The largest buyer was Two Sigma Advisers, adding an estimated $317M. The largest seller was GQG Partners, cutting an estimated $1.06B.
- 1,531 institutional investors held Novo Nordisk (NVO) as of Q1 2025, down from 1,665 in Q4 2024.
- Funds reported $22.5B of Novo Nordisk stock for Q1 2025, down 23% quarter-over-quarter.
- 140 funds opened new Novo Nordisk positions in Q1 2025 and 247 closed out, a net change of -107 holders.
- The largest Novo Nordisk buyer in Q1 2025 was Two Sigma Advisers, an estimated $317M added.
- The largest Novo Nordisk seller in Q1 2025 was GQG Partners, an estimated $1.06B sold.
Based on aggregated 13F filings for Q1 2025.